Article
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
The Lancet. Oncology - 1 Oct 2017
Planchard David, Smit Egbert F, Groen Harry J M, Mazieres Julien, Besse Benjamin, Helland Åslaug, Giannone Vanessa, D'Amelio Anthony M, Zhang Pingkuan, Mookerjee Bijoyesh, Johnson Bruce E
Abstract excerpt
BACKGROUND: BRAFV600E mutation occurs in 1-2% of lung adenocarcinomas and acts as an oncogenic driver. Dabrafenib, alone or combined with trametinib, has shown substantial antitumour activity in patients with previously treated BRAFV600E-mutant metastatic non-small-cell lung cancer (NSCLC). We aimed to assess the activity and safety of dabrafenib plus trametinib treatment in previously untreated patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.